Funding for this supplement provided by Medtronic
cit | Article | November/December 2016 Supplement
cit | News | March 31, 2016
Enrollment Begins in Trial of Medtronic's CoreValve Evolut R TAVR System in Low-Risk Patients
March 31, 2016—Medtronic plc announced that the first patients were enrolled in the expanded indication trial for the CoreValve Evolut R system, the company’s next-generation, recapturable, self-expanding transcatheter aortic valve replacement (TAVR) system.
cit | News | June 4, 2019
Early Feasibility Study Begins for Ancora Heart's AccuCinch Transcatheter Heart Failure Therapy
June 3, 2019—Ancora Heart, Inc. announced the first patient was enrolled in a United States early feasibility study evaluating the company's AccuCinch ventricular repair system as a treatment for patients with reduced ejection fraction systolic heart failure.